The Polynovo (ASX:PNV) share price sank to multi-year lows today. What's going on?

The company's shares finished deep in the red again. We take a closer look.

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares continue to slide, hitting a multi-year low today
  • The company ranks seventh as the most shorted stock on the ASX, at 9%
  • Polynovo is scheduled to release its half-year results later this month

The Polynovo Ltd (ASX: PNV) share price had a tough day on the ASX, touching a new multi-year low of $1.165.

This comes despite the medical device company not releasing any announcements to the ASX in almost a month.

At the close, Polynovo shares were swapping hands for $1.17 apiece, down 3.31%. They are now down 25% this year to date.

Let's take a look at what is impacting the company's share price of late.

Polynovo continues to attract short interest

The negative sentiment around the Polynovo share price continues to attract the attention of investors holding short positions.

Largely, the inconsistent performance of the business regardless of its outlook may have led to a deterioration in the Polynovo share price.

Management previously stated that challenging market conditions caused by COVID-19 created headwinds for the company.

Although the United States reported a surge in sales volumes, as a whole Polynovo missed the mark on investor expectations. This is mainly related to the underperformance achieved in the United Kingdom, Ireland, and Europe.

Last Wednesday, the Australian Securities & Investments Commission (ASIC) released its short position report indicating an increased short interest in Polynovo shares.

As such, Polynovo took up the seventh spot on the list with 9% of its shares being shorted. This represents a 5.7% increase from the start of the month when its shares had a short interest of 8.51%.

Given the scope of short positions being taken up, it is possible investors believe the company's performance will be underwhelming when it reports its half-year results later this month.

About the Polynovo share price

Financial advisory services firm Wilsons cut its 12-month price target for Polynovo shares by 29% to $1.42 in November.

Based on the current Polynovo share price, this implies an upside of roughly 21% for investors.

Looking back, the medical device company's shares fell around 60% in value in 2021. In comparison, the S&P/ASX 200 Healthcare Index (ASX: XHJ) gained around 8% in the same time frame.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Happy healthcare workers in a labs
Healthcare Shares

Up 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time high

This company has busily deployed cash over the past six months while growing at a phenomenal pace.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Broker says this ASX biotech stock could almost double in value

Bell Potter is feeling very bullish about this risky stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Share Gainers

If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!

Mesoblast shares have been on a tear this past month. But why?

Read more »

Woman going for a scan reassured by doctor
Healthcare Shares

How AI could boost this ASX 300 healthcare stock

The Firetrail investment management team see AI providing a 'material tailwind' for this stock.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is the ResMed share price diving 5% today?

Weight loss wonder drugs are weighing heavily on this stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Why is the Telix share price jumping 15% to a record high?

This healthcare stock is scaling new heights on Thursday. But why?

Read more »

Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.
Healthcare Shares

How much do you need to invest in CSL shares for $8,000 in annual dividends?

CSL's dividends are exponentially more valuable for long-term investors.

Read more »

smiling health care workers in a medical setting
Healthcare Shares

'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stock

This healthcare stock has been given a boost from the US FDA today.

Read more »